Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 274 clinical trials
Biological Characterisation of High Risk CHildhood Cancer in Children Adolescents and Young Adults (MICCHADO)

Methodology Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study

bone marrow procedure
mycn
brain tumor
kidney tumors
mycn protein
  • 30 views
  • 23 Jan, 2021
  • 28 locations
JUNIPER: A Phase 2 Study to Evaluate the Safety Biological Activity and PK of ND-L02-s0201 in Subjects With IPF

A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

forced vital capacity
diffusion capacity of the lung for carbon monoxide
carbon monoxide
  • 294 views
  • 26 Jan, 2021
  • 35 locations
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

This study [contRAst 2 (201791: NCT03970837)] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165 in combination with csDMARD(s), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to csDMARD(s) or …

chloroquine
methotrexate
DMARD
arthralgia
sulfasalazine
  • 284 views
  • 03 Mar, 2021
  • 185 locations
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

This study (contRAst 3 [202018: NCT04134728]) is a Phase 3, randomized, multicenter, double-blind study to assess the safety and efficacy of GSK3196165 in combination with conventional (cs) DMARD[s]) or the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to biologic …

chloroquine
methotrexate
DMARD
arthralgia
sulfasalazine
  • 213 views
  • 03 Mar, 2021
  • 151 locations
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

adalimumab
mucosal inflammation
ustekinumab
abdominal pain
infliximab
  • 596 views
  • 03 Mar, 2021
  • 703 locations
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

crohn's disease
immunosuppressive agents
endoscopy
conventional treatment
mucosal inflammation
  • 824 views
  • 03 Mar, 2021
  • 669 locations
Boosting Biologics in UC

This study evaluates the safety of the probiotic compound IDOFORM TRAVEL in patients with ulcerative colitis undergoing anti-TNF treatment with insufficient clinical response. Furthermore, the study aims to explore the composition of the bacteria of the gut as well as the immunological activity in patients with ulcerative colitis undergoing anti-TNF …

remission
adalimumab
colitis
tumor necrosis factor
immunomodulators
  • 3 views
  • 24 Jan, 2021
  • 1 location
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)

It is increasingly recognized that although suppression of inflammation is a treatment goal in rheumatoid arthritis, many people who have control of their inflammation continue to experience pain. A number of studies have recently shown that by measuring further characteristics of pain in rheumatoid arthritis, e.g. neuropathic pain, quantitative sensory …

methotrexate
DMARD
tumour necrosis
tumor necrosis factor alpha
adalimumab
  • 0 views
  • 26 Jan, 2021
  • 1 location
Clinical Study Using Biologics to Improve Multi OIT Outcomes

Food allergy (FA) is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of …

omalizumab
skin pricking
allergen
peanut allergy
milk allergy
  • 57 views
  • 26 Jan, 2021
  • 3 locations
Examination of Efficacy and Safety of Baricitinib in RA Patients

>Biologics treatment for 12 months Tofacitinib treatment for 12 months

baricitinib
tofacitinib
  • 4 views
  • 25 Jan, 2021
  • 1 location